Investigators randomized boys and girls aged 9–10 years in a 1:1 fashion to receive either two doses of nonavalent HPV (9vHPV) or a mixed two-dose schedule combining the bivalent HPV (2vHPV) and 9vHPV vaccine with a six-month interval. The abstract reports an according-to-protocol population of 337 participants at follow-up: 168 in the homologous 9vHPV arm and 169 in the mixed arm, the latter split into 2vHPV then 9vHPV (n = 86) and 9vHPV then 2vHPV (n = 83). The serological assessments used M9ELISA to measure the proportion with detectable antibodies and geometric mean concentrations (GMCs) for the nine 9vHPV-targeted types at 7 months and 36 months after the first dose. The study team reported randomization and follow-up endpoints in the abstract; full protocol details and additional methodology were not included in the abstract text.
At 36 months, antibodies to HPV16 and HPV18 persisted in all 337 participants (100%) across both the homologous and mixed two-dose schedules, the authors reported. For the remaining types included in 9vHPV, seropositivity ranged from 94% to 100% in participants who received a mixed schedule, compared with 100% seropositivity in those who received two doses of 9vHPV. These findings indicate high rates of detectable antibodies across schedules at three years post-first dose, with absolute persistence for the two most oncogenic types recorded in every assessed participant.
The abstract provides GMC point estimates and 95% confidence intervals for HPV16 and HPV18 at 36 months, and notes statistically higher GMCs for these types in the mixed-schedule groups compared with the homologous 9vHPV group. For HPV16, reported GMCs were 184.6 (145.5–234.3) and 151.7 (121.2–189.8) in the two mixed-schedule permutations versus 97.7 (83.6–114.1) for the 9vHPV + 9vHPV group. For HPV18, GMCs were 70.4 (53.5–92.7) and 72.7 (57.0–92.8) in the mixed schedules versus 40.3 (34.9–46.6) in the homologous 9vHPV group. The study team also reported that the sequence 9vHPV + 2vHPV resulted in higher GMCs than the reverse sequence (2vHPV + 9vHPV), at least for HPV16/18.
For HPV types included in the 9vHPV vaccine but not in the 2vHPV formulation—types such as 6, 11, 31, 33, 45, 52, and 58—the abstract indicates somewhat lower seropositivity in the mixed-schedule arm (94–100%) compared with universal 100% seropositivity in the homologous 9vHPV arm at 36 months. The authors observed that GMC ratios comparing homologous to mixed schedules for these non-2vHPV types decreased between the 7-month and 36-month measurements, meaning that early differences in antibody levels diminished over time. The abstract does not supply individual-type GMCs for every non-16/18 type in the text; those data would require consulting the full article.
The study team conducted sex-stratified analyses and reported no substantial differences between boys and girls in antibody persistence or GMC patterns at 36 months. The abstract states that the trajectories and end-point serology were similar across sexes, suggesting comparability of immune response durability for preadolescent males and females within the trial cohort. The abstract does not provide detailed numeric sex-stratified GMCs or formal interaction testing results in the summary text.
The authors concluded that serological responses to mixed two-dose HPV schedules are sustained for at least 36 months and are comparable to a homologous two-dose 9vHPV schedule with respect to HPV16/18. They noted these data supply immunogenicity evidence supporting the feasibility of mixed 2-dose HPV schedules. The abstract also explicitly states that further research on clinical effectiveness (for example, prevention of persistent infection or HPV-related disease endpoints) and implementation considerations is required to inform policy decisions. The trial registration is provided (ClinicalTrials.gov NCT02567955) for readers seeking protocol or registry details not included in the abstract.
The abstract does not list a detailed limitations section, but several constraints are implicit in the information presented: clinical effectiveness outcomes were not reported in the abstract; immunogenicity alone cannot substitute for long-term protection data against infection or disease. The abstract did not include full methodological detail—such as assay cutoffs, handling of missing data, or exact per-protocol definitions—so readers must consult the full text for those specifications. Authors recommended additional research on clinical endpoints and implementation; those are the specific open questions left by this report.
The study team provided a clear serological profile at three years post-first dose, yet the ultimate policy relevance will depend on linking these immunogenicity data to long-term clinical protection and practical programmatic considerations in diverse settings.